Marburg Virus VLP 

Marburg virus-like particles (MARV VLPs) are non-infectious, self-assembled nanoparticles that mimic the morphology and antigenicity of the Marburg virus (MARV) without containing its genetic material. MARV, a member of the Filoviridae family, is a highly pathogenic virus causing severe hemorrhagic fever with high mortality rates. MARV VLPs are a promising platform for vaccine development, diagnostics, and immunological studies to address this critical public health threat.

Structure of MARV VLPs

MARV VLPs are composed of key structural proteins that self-assemble into particles resembling the native virus:

  • Glycoprotein (GP): Facilitates viral entry into host cells by mediating attachment and fusion, and is a primary target for neutralizing antibodies.
  • Matrix Protein (VP40): Drives VLP assembly and budding from host cells, forming the structural backbone of the particle.
  • Nucleoprotein (NP): Mimics the nucleocapsid structure of MARV and enhances VLP immunogenicity.
Production Systems

MARV VLPs can be produced using various expression systems:

  • Mammalian Cells: Preferred for producing glycoproteins (GP) with authentic post-translational modifications essential for proper antigenicity.
  • Insect Cells: Baculovirus expression systems are widely used for scalable and cost-effective production.
  • Plant-Based Systems: Emerging as an economical and scalable alternative for vaccine and diagnostic applications.
Applications
  • Vaccines
    • Prophylactic Vaccines: MARV VLP-based vaccines aim to induce strong immune responses, particularly neutralizing antibodies targeting the GP protein, to protect against Marburg virus infection.
  • Diagnostics
    • MARV VLPs serve as antigens in serological assays to detect MARV-specific antibodies, aiding in disease surveillance and diagnosis during outbreaks.
  • Immunological Research
    • Used to study MARV-host interactions and immune responses, particularly mechanisms of neutralization and T-cell activation.

Marburg virus-like particles are a safe and effective platform for combating MARV infections through vaccines, diagnostics, and therapeutic applications. With their ability to closely mimic the native virus without the risk of infection, MARV VLPs hold significant promise in addressing this severe viral threat. Advances in VLP technology aim to overcome existing challenges, enhancing their role in global health efforts against MARV and other emerging filoviruses.

AffiVLP® Marburg virus VLP (VP40; NP Proteins)
CAT# AFG-VLP-255
Size: 100 µg
For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD
AffiVLP® Marburg virus VLP (VP40 Proteins)
CAT# AFG-VLP-253
Size: 100 µg
For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD